Hong Zhang1, Dongxiu Zhang1, Hailong Lin1, Leting Huang2. 1. The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 109th Xueyuanxi Road, Wenzhou, Zhejiang Province, China. 2. The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 109th Xueyuanxi Road, Wenzhou, Zhejiang Province, China. windflakelin@163.com.
Abstract
OBJECTIVES: In this study, Problem Management Plus (PM+) was used for patients with multiple myeloma (MM), to develop a care model of psychology and quality of life. METHODS: Forty cases received psychological management (PM+ group), and 40 cases underwent investigation without management (non-PM+ group). Patients were assessed using PSYCHLOPS, WHO DAS 2.0, and HADS (see Supplementary File 1). RESULTS: The results showed that the PM+ group showed reductions in Psychological Outcome Profile scores (6.3 ± 2.9) following program completion (preprogram scores: 16.0 ± 1.9, P < .05). The non-PM+ group showed differences between preprogram (16.7 ± 1.8) and postprogram scores (14.8 ± 2.6, P < .05). The effect size of the PM+ group exceeded that of the non-PM+ group (5.1 to 1.0). In the Hospital Anxiety and Depression Scale, the PM+ group showed reductions in anxiety (6.4 ± 1.8) and depression (5.4 ± 0.7) (preprogram scores: 14.7 ± 4.3, P < .05 and 10.9 ± 2.6, P < .05, respectively). In the Hospital Anxiety and Depression Scale, scores for mobility, self-care, getting along, life activities, and participation decreased in the PM+ group following program completion (all P's < .05) but did not decrease in the non-PM+ group (all P > .05). CONCLUSION: The PM+ strategy could help patients to alleviate symptoms of anxiety and depression and strengthen social support, to aid in the management of problems and improve mental disorders. IMPACT STATEMENT: MM patients often experienced mental disorders and wished to participate in psychosocial interventions; the PM+ strategies should be as a wide to help patients manage their problems and alleviate the symptoms of anxiety and depression.
OBJECTIVES: In this study, Problem Management Plus (PM+) was used for patients with multiple myeloma (MM), to develop a care model of psychology and quality of life. METHODS: Forty cases received psychological management (PM+ group), and 40 cases underwent investigation without management (non-PM+ group). Patients were assessed using PSYCHLOPS, WHO DAS 2.0, and HADS (see Supplementary File 1). RESULTS: The results showed that the PM+ group showed reductions in Psychological Outcome Profile scores (6.3 ± 2.9) following program completion (preprogram scores: 16.0 ± 1.9, P < .05). The non-PM+ group showed differences between preprogram (16.7 ± 1.8) and postprogram scores (14.8 ± 2.6, P < .05). The effect size of the PM+ group exceeded that of the non-PM+ group (5.1 to 1.0). In the Hospital Anxiety and Depression Scale, the PM+ group showed reductions in anxiety (6.4 ± 1.8) and depression (5.4 ± 0.7) (preprogram scores: 14.7 ± 4.3, P < .05 and 10.9 ± 2.6, P < .05, respectively). In the Hospital Anxiety and Depression Scale, scores for mobility, self-care, getting along, life activities, and participation decreased in the PM+ group following program completion (all P's < .05) but did not decrease in the non-PM+ group (all P > .05). CONCLUSION: The PM+ strategy could help patients to alleviate symptoms of anxiety and depression and strengthen social support, to aid in the management of problems and improve mental disorders. IMPACT STATEMENT: MMpatients often experienced mental disorders and wished to participate in psychosocial interventions; the PM+ strategies should be as a wide to help patients manage their problems and alleviate the symptoms of anxiety and depression.
Entities:
Keywords:
Anxiety; Depression; Intervention; Multiple myeloma; Problem Management Plus
Authors: S Vincent Rajkumar; Meletios A Dimopoulos; Antonio Palumbo; Joan Blade; Giampaolo Merlini; María-Victoria Mateos; Shaji Kumar; Jens Hillengass; Efstathios Kastritis; Paul Richardson; Ola Landgren; Bruno Paiva; Angela Dispenzieri; Brendan Weiss; Xavier LeLeu; Sonja Zweegman; Sagar Lonial; Laura Rosinol; Elena Zamagni; Sundar Jagannath; Orhan Sezer; Sigurdur Y Kristinsson; Jo Caers; Saad Z Usmani; Juan José Lahuerta; Hans Erik Johnsen; Meral Beksac; Michele Cavo; Hartmut Goldschmidt; Evangelos Terpos; Robert A Kyle; Kenneth C Anderson; Brian G M Durie; Jesus F San Miguel Journal: Lancet Oncol Date: 2014-10-26 Impact factor: 41.316
Authors: Janneke A J Rood; Corien M Eeltink; Florence J van Zuuren; Irma M Verdonck-de Leeuw; Peter C Huijgens Journal: J Clin Nurs Date: 2014-06-03 Impact factor: 3.036
Authors: Katie S Dawson; Richard A Bryant; Melissa Harper; Alvin Kuowei Tay; Atif Rahman; Alison Schafer; Mark van Ommeren Journal: World Psychiatry Date: 2015-10 Impact factor: 49.548
Authors: Atif Rahman; Naila Riaz; Katie S Dawson; Syed Usman Hamdani; Anna Chiumento; Marit Sijbrandij; Fareed Minhas; Richard A Bryant; Khalid Saeed; Mark van Ommeren; Saeed Farooq Journal: World Psychiatry Date: 2016-06 Impact factor: 49.548
Authors: Martin Matzka; Hanna Mayer; Sabine Köck-Hódi; Christina Moses-Passini; Catherine Dubey; Patrick Jahn; Sonja Schneeweiss; Manuela Eicher Journal: PLoS One Date: 2016-04-28 Impact factor: 3.240
Authors: Julia Spaaij; Nikolai Kiselev; Christine Berger; Richard A Bryant; Pim Cuijpers; Anne M de Graaff; Daniela C Fuhr; Mahmoud Hemmo; David McDaid; Hanspeter Moergeli; A-La Park; Monique C Pfaltz; Matthis Schick; Ulrich Schnyder; Anna Wenger; Marit Sijbrandij; Naser Morina Journal: Eur J Psychotraumatol Date: 2022-01-31
Authors: Roberto Mediavilla; Kerry R McGreevy; Mireia Felez-Nobrega; Anna Monistrol-Mula; María-Fe Bravo-Ortiz; Carmen Bayón; Beatriz Rodríguez-Vega; Pablo Nicaise; Audrey Delaire; Marit Sijbrandij; Anke B Witteveen; Marianna Purgato; Corrado Barbui; Federico Tedeschi; Maria Melchior; Judith van der Waerden; David McDaid; A-La Park; Raffael Kalisch; Papoula Petri-Romão; James Underhill; Richard A Bryant; Josep Maria Haro; José Luis Ayuso-Mateos Journal: Digit Health Date: 2022-10-05